Patients with cancer treated with immune checkpoint inhibitors (ICIs) have a higher risk of developing psoriasis than those receiving chemotherapy or targeted therapy. A study of 135,230 patients found that ICI users were more than twice as likely to develop psoriasis compared to non-ICI users. Adjusted for demographic factors and comorbidities, the risk remained significant. The findings highlight the importance of monitoring skin health in cancer patients receiving ICIs. However, the study did not account for lifestyle and genetic factors or severity of psoriasis. The results may only apply to PD-1 and PD-L1 inhibitors. The study was published in JAMA Dermatology.
Source link
ICIs Associated With Twofold Increased Psoriasis Risk
